Previous 10 | Next 10 |
2024-01-10 22:09:45 ET Summary ResMed, a leader in digital health with over 22.5 million cloud-connected devices sold, excels in treating respiratory disorders like sleep apnea, impacting over 1 billion globally. Recent data from ResMed challenges the misconception that GLP-1 obes...
2024-01-10 21:40:49 ET Summary ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow significantly in the coming years. Despite being ...
2024-01-09 12:38:56 ET Summary Today, we take our first look at ResMed Inc., a San Diego-based company with two primary business segments: Sleep and Respiratory Care, and Software as a Service. The company's products and services are aimed at a huge global market and ResMed is see...
2024-01-08 10:48:11 ET Summary A list of high-quality dividend growth stocks is identified based on proximity to 52-week lows. Pfizer, Bristol-Myers Squibb, and ResMed appear attractively valued based on Future and Historical fair valuations. Chevron appears to be a good inves...
2024-01-05 13:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed manage...
SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific ...
2023-12-20 17:31:56 ET More on ResMed ResMed: Down 60% With Tremendous Long-Term Potential ResMed: Weight-Loss Drug Worries Provide Buying Opportunity ResMed Inc. (RMD) Q1 2024 Earnings Call Transcript ResMed secures victory in patent fight against New York U...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. Thi...
2023-12-11 16:28:13 ET More on ResMed ResMed: Down 60% With Tremendous Long-Term Potential ResMed: Weight-Loss Drug Worries Provide Buying Opportunity ResMed Inc. (RMD) Q1 2024 Earnings Call Transcript ResMed issues urgent safety notice over magnetic CPAP mas...
News, Short Squeeze, Breakout and More Instantly...
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 7.11% on an annualized basis producing an average annual return of 15.03%. ...
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio a...
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7%...